Asset profile
Pomalidomide
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 8 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pomalidomide: this drug | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Cereblon (CRBN) | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Thalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Iberdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Mezigdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Cemsidomide | Phase 2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| ICP-490 | Phase 1/2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| HRS-3738 | Phase 1 | Multispecific antibody | Cereblon (CRBN) | ||
| TQB3820 | Phase 1 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) |
…and 53 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Lenalidomide · Multiple Myelomavs Thalidomide · Multiple Myelomavs ICP-490 · Multiple Myelomavs Iberdomide · Multiple Myelomavs Mezigdomide · Multiple Myelomavs Cemsidomide · Multiple Myeloma
2 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(66 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (9)
October 2026 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2026-10-31 · NCT05581875 · CT.gov ↗
What to watch
November 2026 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
December 2026 (7)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT01562405 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)Recruiting
Est. primary completion 2026-12 · NCT06855823 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT02718833 · CT.gov ↗
What to watch
Phase 2Systemic AmyloidosisRecruiting
Est. primary completion 2026-12 · NCT06342466 · CT.gov ↗
What to watch
Phase 1Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated LymphomasRecruiting
Est. primary completion 2026-12-01 · NCT04902443 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04883242 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06924424 · CT.gov ↗
What to watch
2027 (27)
January 2027 (2)
February 2027 (2)
March 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
Phase 1/2HIV-1 InfectionActive not recruiting
Est. primary completion 2027-03-31 · NCT06660498 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT06508983 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-01 · NCT04835129 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04108195 · CT.gov ↗
What to watch
May 2027 (2)
July 2027 (2)
August 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-08-16 · NCT06106945 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04790474 · CT.gov ↗
What to watch
October 2027 (4)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT05556798 · CT.gov ↗
What to watch
Phase 1Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-10 · NCT07532525 · CT.gov ↗
What to watch
Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-10-15 · NCT04850599 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaRecruiting
Est. primary completion 2027-10-21 · NCT05208307 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
December 2027 (6)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07138209 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2027-12 · NCT06742138 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 1/2Indolent LymphomaNot yet recruiting
Est. primary completion 2027-12-05 · NCT07441954 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05651932 · CT.gov ↗
What to watch
2028 (15)
January 2028 (1)
Phase 1Kaposi SarcomaActive not recruiting
Est. primary completion 2028-01-01 · NCT02659930 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT06879379 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)Recruiting
Est. primary completion 2028-03-31 · NCT07523737 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Malignant Plasma Cell NeoplasmsNot yet recruiting
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch
Phase 1Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell NeoplasmRecruiting
Est. primary completion 2028-06-01 · NCT05389423 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (2)
October 2028 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-10-31 · NCT07555938 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
2029 (9)
January 2029 (3)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07757412 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-03-31 · NCT07463807 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
November 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-11 · NCT07772024 · CT.gov ↗
What to watch
2030 (2)
2033 (4)
January 2033 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2033-01 · NCT07831122 · CT.gov ↗
What to watch
February 2033 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-02 · NCT07728188 · CT.gov ↗
What to watch
March 2033 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2033-03 · NCT07748689 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.